These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 3385720)
41. Pharmacoepidemiology of tacrine in Alzheimer's disease. Begaud B; Haramburu F; Miremont G Methods Find Exp Clin Pharmacol; 1996; 18 Suppl B():77-8. PubMed ID: 8899701 [No Abstract] [Full Text] [Related]
42. Protection against ischemic injury in primary cultured mouse astrocytes by bis(7)-tacrine, a novel acetylcholinesterase inhibitor [corrected]. Wu DC; Xiao XQ; Ng AK; Chen PM; Chung W; Lee NT; Carlier PR; Pang YP; Yu AC; Han YF Neurosci Lett; 2000 Jul; 288(2):95-8. PubMed ID: 10876069 [TBL] [Abstract][Full Text] [Related]
43. Tacrine-based Multifunctional Agents in Alzheimer's Disease: An Old Story in Continuous Development§. Milelli A; De Simone A; Ticchi N; Chen HH; Betari N; Andrisano V; Tumiatti V Curr Med Chem; 2017; 24(32):3522-3546. PubMed ID: 28294041 [TBL] [Abstract][Full Text] [Related]
44. Clinical trials with velnacrine: (PROPP) the physician reference of predicted probabilities--a statistical model for the estimation of hepatotoxicity risk with velnacrine maleate. Hardiman S; Miller K; Murphy M Acta Neurol Scand Suppl; 1993; 149():46-52. PubMed ID: 8128839 [TBL] [Abstract][Full Text] [Related]
45. Effects of 9-amino-1,2,3,4-tetrahydroacridine (THA), a potential drug for treatment of Alzheimer's disease, on the physical state of human erythrocyte membranes. Palmieri DA; Butterfield DA Prog Clin Biol Res; 1989; 292():419-24. PubMed ID: 2726917 [No Abstract] [Full Text] [Related]
46. Alzheimer's disease: the role of tacrine therapy. Jogerst G Iowa Med; 1995 Oct; 85(10):409-11. PubMed ID: 7591656 [No Abstract] [Full Text] [Related]
47. Tacrine. Alzheimer's disease and the cholinergic theory. A critical review and results of a new therapy. Boller F; Orgogozo JM Neurologia; 1995 May; 10(5):194-9. PubMed ID: 7619536 [No Abstract] [Full Text] [Related]
48. Some possibilities of protection against acetylcholinesterase inhibition by organophosphates in vivo. Bajgar J; Patocka J; Fusek J; Hrdina V Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1984; 27(4):425-35. PubMed ID: 6599819 [No Abstract] [Full Text] [Related]
50. What have we learned from the THA trials to facilitate testing of new AChE inhibitors. Gauthier S; Gauthier L Prog Brain Res; 1993; 98():427-9. PubMed ID: 8248532 [No Abstract] [Full Text] [Related]
54. Cholinergic delirium and neurotoxicity associated with tacrine for Alzheimer's dementia. Trzepacz PT; Ho V; Mallavarapu H Psychosomatics; 1996; 37(3):299-301. PubMed ID: 8849507 [No Abstract] [Full Text] [Related]
55. Love and terror. Is a chemical messenger key to treating Alzheimer's? Erickson D Sci Am; 1991 Apr; 264(4):148, 150. PubMed ID: 1876819 [No Abstract] [Full Text] [Related]
56. Tacrine: first drug approved for Alzheimer's disease. Crismon ML Ann Pharmacother; 1994 Jun; 28(6):744-51. PubMed ID: 7919566 [TBL] [Abstract][Full Text] [Related]
57. Alzheimer's disease: a treatment in sight? Lovestone S; Howard R J Neurol Neurosurg Psychiatry; 1995 Dec; 59(6):566-7. PubMed ID: 7500092 [No Abstract] [Full Text] [Related]
58. Treating Alzheimer's disease with cholinergic drugs, Part I. Terpstra T; Terpstra T Nurse Pract; 1998 Nov; 23(11):90, 92, 97 passim. PubMed ID: 9834506 [No Abstract] [Full Text] [Related]
59. Maximizing function in Alzheimer's disease: what role for tacrine? Smucker WD Am Fam Physician; 1996 Aug; 54(2):645-52. PubMed ID: 8701842 [TBL] [Abstract][Full Text] [Related]
60. [Clinical study of patients with Alzheimer's disease under treatment with tacrine]. García-López MT; Guardado-Santervás P Rev Neurol; 2001 Feb 16-28; 32(4):394-7. PubMed ID: 11398762 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]